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ABSTRACT
Enhanced radiosensitivity at low doses of ionizing radiation (IR) (0.2 to 0.6 Gy) 
has been reported in several cell lines. This phenomenon, known as low doses hyper-
radiosensitivity (LDHRS), appears as an opportunity to decrease toxicity of radiotherapy 
and to enhance the effects of chemotherapy. However, the effect of low single doses 
IR on cell death is subtle and the mechanism underlying LDHRS has not been clearly 
explained, limiting the utility of LDHRS for clinical applications. To understand the 
mechanisms responsible for cell death induced by low-dose IR, LDHRS was evaluated 
in DLD-1 human colorectal cancer cells and the expression of 80 microRNAs (miRNAs) 
was assessed by qPCR array. Our results show that DLD-1 cells display an early DNA 
damage response and apoptotic cell death when exposed to 0.6 Gy. miRNA expression 
profiling identified 3 over-expressed (miR-205-3p, miR-1 and miR-133b) and 2 down-
regulated miRNAs (miR-122-5p, and miR-134-5p) upon exposure to 0.6 Gy. This miRNA 
profile differed from the one in cells exposed to high-dose IR (12 Gy), supporting a 
distinct low-dose radiation-induced cell death mechanism. Expression of a mimetic miR-
205-3p, the most overexpressed miRNA in cells exposed to 0.6 Gy, induced apoptotic 
cell death and, more importantly, increased LDHRS in DLD-1 cells. Thus, we propose 
miR-205-3p as a potential radiosensitizer to low-dose IR.
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INTRODUCTION
Radiotherapy (RT) is the standard treatment for most 
cancers, including colorectal cancer (CRC). It has been 
estimated that 60% of patients with solid cancers have 
received or will receive RT at least once at some point 
during their disease, and for 15% of these patients RT is 
the only treatment that will receive [1, 2]. Conventional 
RT protocols for a localized solid tumor include the 
administration of high-dose (60–70 Gy) ionizing radiation 
(IR), delivered in about 30 to 35 doses (2 Gy per day). 
These protocols are very effective, but are not free of 
toxicity and secondary side effects [3, 4–7]. 
The linear-quadratric (LQ) model has been 
widely used to predict the effects on cell survival after 
the exposure to IR. This model is generally used for 
calculating the effect of doses in a RT treatment. The 
curvilinear approach of LQ model show a correlation 
between cell death and IR at doses ≥ 2 Gy [1–4], assuming 
little or even no effect at lower doses (≤ 1 Gy) [8–11]. 
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However, an increase in cell death has been observed in 
a tight range of low doses (0.2 to 0.6 Gy [12, 13]). This 
phenomenon, known as low doses hyper-radiosensitivity 
(LDHRS), is followed by an increase in radioresistance 
at dose closer to 1 Gy [9, 14–17]. LDHRS has been 
observed in ~75% of the 50 cell lines tested in vitro to 
date including, for example colorectal (HT29 and RKO) 
[18, 19], bladder (RT112) [20], lung (A549) [21], 
melanoma (MeWo) [22] among others. In addition, 
LDHRS has been also shown in Multicellular tumor 
spheroids (MCTSs) built up with breast cancer cells 
[17] and also in non-tumor cells such as fibroblast, 
keratinocytes and lung epithelial cells [23]. This LDHRS 
phenomenon appears as an opportunity to decrease the IR 
doses used in RT [9, 11, 15, 24–26], decreasing toxicity 
and side effects of conventional therapy. In addition, it was 
reported that serum from 0.3–0.03 Gy irradiated DBA/2 
mice allowed an increased radioresistance and viability 
of non-irradiated breast and glioblastoma cell lines [27], 
which suggested that exposure to low doses IR would also 
diminish bystander effect of RT.
Even though LDHRS is very efficient in killing cells 
per dose unit, [1, 21, 25, 28] the total cytotoxic effects 
gained with such low doses are not enough to achieve 
therapeutic effect in a single low-dose fraction. However, 
its benefit has been successfully exploited by using Low 
Doses Fractionated Radiotherapy (LDFRT). In this sense, 
spreading the total dose into short, low-dose pulses has 
been shown to effectively limit the undesirable tissue 
toxicity as well as to reduce complications [29–31].
Nevertheless, when radiation is used alone as 
LDFRT, complications are minimized, but the final 
clinical outcome is not necessarily improved. Importantly, 
preclinical as well as clinical studies have reported that 
using LDFRT in a chemo-radiotherapy regimen enhances 
the effect of chemotherapy, achieving maximum tumor 
cell killing with significantly reduced toxicity [1, 31–33].
Thus, pulsed low dose fractionated radiation has 
been validated in pre-clinical and clinical studies, although 
the molecular basis of reduced necrosis and preserved 
normal tissue integrity has remained unclear [29]. Given 
that low-dose IR causes DNA damage [34], LDHRS has 
been associated with a DNA damage response. However, 
it has been reported that damaged DNA in fibroblasts is 
repaired before 24 hours [35], thus the exact mechanism 
inducing LDHRS remains unknown. Understanding 
the molecular mechanism behind LDHRS would give 
an opportunity to potentiate its beneficial effects either 
standing alone or in radio-chemotherapy regimens. This 
could be achieved through biological strategies to further 
enhance the effectiveness and efficiency of RT or by 
identifying tumor biomarkers that could allow a more 
precise selection of the better regime for each individual 
patient [36].
Considering the complexity of the cellular response 
to IR, it is reasonable to hypothesize that one type of 
molecules that could be involved in the mechanism of 
LDRHS were microRNAs (miRNAs or miRs), given 
their broad effect on gene expression. These are a class 
of non-coding, endogenous, short (~22 nucleotides) and 
single-stranded RNAs that act at the post-transcriptional 
level as regulators of gene expression. They bind to the 
untranslated region of mRNA targets, inducing either their 
degradation or translational repression [37, 38]. Because 
of its role in the regulation of gene expression, miRNAs 
play a key role in different cellular processes. Several 
studies have evaluated the impact of high-dose IR on 
miRNA expression, with little attention paid to the effects 
of low doses. For instance, it has been reported that human 
colonic epithelial cells modulate miRNA expression 
in response to high-dose IR (> 2 Gy) [39]. In addition, 
transfection with mimetic miRNAs, such as miR-31-5p 
[40], miR-100 [41], miR-630 [42] and miR-124 [43], or 
inhibition of miR-622 [44] and miR-221 [45], resulted in 
an increase of radiosensitivity at high- dose IR (4 Gy) in 
several CRC cell lines. 
Changes in miRNA profiles after exposure to low-
dose radiation have also been reported [46–50]. However, 
modulation of miRNA expression and its effects on 
radiosensitivity in a LDRHS context has not been 
completely explored. In this study, we evaluated LDHRS 
and analyzed the expression of a panel of 80 miRNAs, 
all related to cell proliferation or cell death, in DLD-1 
human colorectal cancer cells exposed to 0.6 and 12 Gy. 
Our results show that five miRNAs (3 up-regulated and 2 
down-regulated) are differentially expressed in low-dose 
irradiated DLD-1 cells. Moreover, overexpression of one 
of them, miR-205-3p, induced cell death and increased 
radiosensitivity to low-doses in DLD-1 cells. 
RESULTS
DLD-1 colorectal cancer cells show LDHRS at 
0.6 Gy
To assess whether DLD-1 colorectal cancer cells 
displayed LDHRS, first they were irradiated with low 
(0.3 and 0.6 Gy) or high radiation doses (1, 6 and 12 
Gy) and viability was evaluated by MTS at 24, 48 and 
72 h after IR. At 48 h post IR, a significant reduction 
in viability was detected in cells exposed to 0.6 Gy and 
12 Gy compared to control cells (0 Gy) (Figure 1A). 
As comparison and as previously reported, HT-29 cells 
were irradiated using the same doses, which showed 
a slight decrease in viability (~10%) at 0.3–0.6 Gy 
(Supplementary Figure 2) [15, 18, 51].
A decrease in DLD-1 viability upon IR was 
confirmed by trypan blue exclusion assay. In cells exposed 
to 0.6 Gy the most significant increase in cell death was 
observed 48 h after IR, supporting previous results (Figure 
1B). At this time point, cells exposed to 0.6 Gy displayed 
higher sensitivity than cells exposed to 1 Gy (Figure 1B). 
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To confirm radiosensitivity in DLD-1 cells, a clonogenic 
assay was performed. As expected, high doses of IR 
elicited an important cell death but, more importantly, cells 
exhibited a decrease in survival at 0.3 and 0.6 Gy along 
with an increase in radioresistence at 1 Gy (Figure 1C), 
suggesting that LDHRS occurred [9, 13, 14]. In order to 
confirm LDHRS in these cells, data from clonogenic assay 
was mathematically modeled using the linear-quadratic 
[8, 52] and induced-repair models [10, 21, 31] (Figure 1C). 
Determination coefficients, R2, showed a better fitted curve 
when the induced-repair model was used. Furthermore, 
initial slope derived from induced-repair model (as) was 
greater than initial slope value (ar) extrapolated from 
linear-quadratic model (as/ar = 3.4). All this data confirm 
the occurrence of LDHRS in these cells.
To assess whether low-dose IR-induced cell death 
was a result of apoptosis, we evaluated caspase 3/7 
activation in IR cells. Our results showed that 0.6 Gy 
induced a significant increase in caspase 3/7 activity at 
48 and 72 h after IR (Figure 2A). Likewise, an increase in 
DNA fragmentation was also evidenced by an enrichment 
of the SubG1 cell population (Figure 2B). Importantly, no 
cytotoxicity (evaluated by protease release) was found in 
cells exposed to 0.6 Gy (Figure 2C). Unlike 0.6 Gy, higher 
doses (12 Gy) triggered both apoptotic and necrotic cell 
death (Figure 2). 
An early DNA damage response is elicited at 0.6 Gy
In order to confirm previous data showing DNA 
damage response in other cell models exposed to low 
doses IR [53, 54] phosphorylation of H2AX histone 
(γ-H2AX) -a DSB surrogate marker- was analyzed. 
In cells exposed to 0.6 Gy, γ-H2AX nuclear foci were 
detected 30 min after IR and the number of foci becomes 
to decrease 3 h after IR (Figure 3A and 3B). Thus, 6 h 
Figure 1: Low doses of IR reduce viability of DLD-1 cells. (A) Viability of DLD-1 cells determined by MTS assay at different 
times and different doses of irradiation. Results are expressed as a percentage of control at each time point. (B) Cell death was evaluated 
with trypan blue dye exclusion assay. Data from clonogenic assay was modeled using (C) lineal-quadratic (LQ) model and induced-repair 
(IR) model. In A and B, results are expressed relative to control. Means ± S.D. of at least 3 independent experiments are shown. *P < 0.05; 
**P < 0.01; ***P < 0.001, two-way ANOVA.
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after IR, no significant differences between irradiated and 
control cells (0 Gy) were observed (Figure 3A and 3B). 
These results were confirmed by a western blot assay of 
γ-H2AX at same times (Figure 3C). On the other hand, 
in cells exposed to 12 Gy, elevated γ-H2AX levels and 
nuclear foci were still persistent 48 h after IR (Figure 3). 
Along with γ-H2AX foci formation, early but slight 
increase in Ser15-phosphorylation of P53 (Figure 4A), 
phospho-CHK1 (Figure 4B) and phospho-CHK2 were 
also observed (Figure 4C), indicating the activation of a 
DNA damage response.
High and low IR doses induce differential 
microRNA expression
In order to study whether miRNAs could be 
involved in the mechanism of LDHRS, cells were IR 
with 0.6 and 12 Gy and, 48 h later, qPCR array was 
performed to evaluate the expression of a subset of 
86 miRNAs (80 associated with proliferation and 
apoptosis; and 6 housekeeping genes) (Supplementary 
Table 1). When compared to the control group, five 
differentially expressed miRNAs (adjusted P < 0.05) 
were identified in cells IR with 0.6 Gy, of which three 
were augmented (miR-205-3p, miR-1 and miR-133b) 
and two diminished (miR-122-5p and miR-134-5p) 
(Figure 5A and Table 1). On the other hand, only 
4 miRNAs were differentially incremented (miR-
512-5p, miR-218-5p, miR-449a and miR-1) with no 
differentially decreased miRNAs in cells exposed to 
12 Gy (Figure 5B and Table 2). Interestingly, only one 
miRNA (miR-1) was deregulated to both radiation doses 
(0.6 and 12 Gy), indicating that most of miRNAs levels 
studied are IR dose-dependent (Figure 5C). 
In order to validate our findings, RT-qPCR were 
carried out to assess the level of mRNA targets of the most 
differentially regulated miRNAs: VEGF-A for miR-205-3p 
(predicted with miRbase and TargetScan 7.1) (Figure 6A), 
PKCε for miR-1 [55] (Figure 6B), MMP9 for miR-133b [56] 
(Figure 6C) and NOD2 [57] (Figure 6D) for miR-122-5p. 
As expected, targets of the most augmented miRNAs at 0.6 
Gy showed reduced mRNA levels (Figure 6A–6C), while 
Figure 2: Low doses of IR increase apoptosis in DLD-1 cells. (A) Caspase 3/7 activity was evaluated using a luminescence 
assay. (B) SubG1 population was evaluated by flow cytometry. (C) Citotoxicity was evaluated by release of intracellular proteases using 
a fluorometric kit detection. Results are expressed relative to control. Means ± S.D. of at least 3 independent experiments are shown. 
*P < 0.05; **P < 0.01; ***P < 0.001, two-way ANOVA.
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Figure 3: IR-induced DSB in DLD-1 cells. (A) Evaluation of double strand break (DSBs) by immunofluorescence staining for 
γ-H2AX 48 h after irradiation. Nuclei were stained with DAPI. (B) γ-H2AX foci (Green) were quantified and normalized to the number of 
nuclei (Red). Cells were counted in 5 different fields and at least 100 cells were evaluated per sample. (C) A representative blot of γ-H2AX 
expression is shown along with a graph of the densitometry assay of the signal. The γ-H2AX signal was normalized to β-actin (loading 
control). Data represent the means ± S.D. of at least 3 independent experiments. *P < 0.05, ***P < 0.001, Two-way ANOVA.
the miR-122-5p target, NOD2, showed an increased mRNA 
level (Figure 6D). On the contrary, high doses of 12 Gy IR 
only showed impact on MMP9 mRNA levels (Figure 6C), 
with no effect on the expression of the other targets analyzed.
Altogether, our data shows that DLD-1 cells display 
LDHRS, which is associated with differential miRNA and 
targets profiles. 
MiR-205-3p overexpression increases LDHRS.
To evaluate whether the most augmented miRNA 
in response to 0.6 Gy (miR-205-3p) had an effect on 
radiosensitivity at low doses, DLD-1 cells were transfected 
with a miR-205-3p mimic. A MTS assay showed that 
overexpression of miR-205-3p reduced viability in both 
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absence of IR and doses IR of 0.6 and 12 Gy. Transfection 
of an anti-miR-205-3p (inhibitor) had no effect on viability 
(Figure 7A). To evaluate the effect of the mimetic miR-205-
3p on proliferation, a mitosis specific marker (Phospho-
histone H3) was used. Interestingly, overexpression of 
miR-205-3p significantly reduced proliferation only in 
the absence of IR (Figure 7B). However, the mimetic 
miR had no effect on cell cycle distribution either in the 
control or in the IR cells (Supplementary Figure 1). On 
the other hand, when the effect of the mimetic miR on cell 
death was evaluated, a significant but distinct response 
was observed in IR cells with 0.6 and 12 Gy. At 48 h after 
IR, cell death increased only in cells exposed to 0.6 Gy 
(Figure 7C). When the effect of the mimetic miR was 
evaluated on apoptosis by assessing the sub-G1 population, 
a significant increase in cell death was observed in cells 
exposed to 0.6 Gy as early as 24 h after IR (Figure 7D). In 
addition, the radiosensititizer effect of mimetic miR at 12 
Gy was evident only at later time points (72 h) (Figure 7D). 
Interestingly, with 12 Gy, mimetic miR-205-3p induced 
formation of multi- and micronucleated cells, features 
associated with mitotic catastrophe (Figure 7E and 7F). 
This effect was not seen in cells exposed to 0.6 Gy (data 
not shown).
In order to confirm the effect of miR-205-3p on 
LDHRS, DLD-1 cells were transfected with the mimetic 
miR or control (Mock), and then exposed to different 
doses of IR and a colony formation assay was performed 
Consistent with the previous results, miR-205-3p 
overexpression increased radiosensitivity in about 23% 
of cells exposed to 0.6 Gy compared to mock-transfected 
cells (Figure 8). Importantly, transfection with miR-205-
3p significantly increased DLD1-1 radiosensitivity only 
at low-doses range (0–1 Gy), confirming the effect on 
LDHRS. The radiosensitizer effect of miR-205-3p was 
also evaluated in other cell lines, with distinct results. 
In HT29 colon cancer cells, miR-205-3p increased 
radiosensitivity at doses above 1 Gy, while in MCF7 
and MCF10A breast cancer cells, miR-205-3p had no 
effect on radiosensitivity at any of the analyzed doses 
(Supplementary Figure 2). 
DISCUSSION
For some time, radiotherapy (RT) has been one of 
the most often used techniques in cancer treatment. In 
fact, it is estimated that 60% of patients with solid cancers 
have received or will receive RT at least once during the 
Figure 4: Low doses of radiation activate DNA damage repair proteins. (A) Phosphorylation of P53 (ser 15, Figure 3, A), 
pCHK1 (B) and pCHK2 (C) at different times after 0.6 Gy of radiation, was evaluated by western blot. Signals of pP53, pChk1 and 
pChk2 were normalized by their respective total proteins. Data represent means ± S.D. of at least 3 independent experiments. *P < 0.05, 
***P < 0.001, Two-way ANOVA shown as fold changes relative to control.
Oncotarget26393www.oncotarget.com
course of their illness, and for 15% of these patients, RT 
is the only treatment that they will receive [1]. In the 
United States, about 490,000 patients received RT in 2015, 
and this demand will increase by ~20% in 2025 [58]. 
Different devices for radiation delivery are currently used 
in clinical and RT protocols. These are based on exposing 
the tumor area to very high doses of radiation in order to 
induce tumor cell death. However, detrimental effects on 
surrounding normal tissue and several side effects have 
been reported [5, 6, 59]. 
In this context, LDHRS could be a possible way to 
induce cell death using lower doses than those currently 
used in RT [25]. In fact, our results show that DLD-
1colorectal cancer cells exposed to 0.6 Gy elicit a death 
response. Even when all the doses that were tested elicited 
a cell death response (Figure 1B), 1 Gy had a lower effect 
than 0.6 Gy, which is in accordance with the LDHRS 
phenomenon [9, 14, 60]. Moreover, survival results at low 
dose fitted to the induced repair model and not to the LQ 
one, confirming the LDRHS in these cells [14, 61].
Martin et al. noted that ~75% of the 50 cell lines 
tested in vitro (non-tumor and tumor cells) are LDHRS 
positive, including malignant cells of colorectal, glioma, 
breast, prostate, melanoma, bladder, cervix, lung, oral, 
head and neck cancers. However, LDHRS has not been 
explored in DLD-1 cells before [9]. To support our 
analysis, HT-29 cells, previously reported as LDHRS 
positive at doses of <0.5 Gy [15, 18, 51], were irradiated 
and 0.3 Gy was found to cause a slight decrease in 
viability (~10%, Supplementary Figure 2).
Apoptosis and necrosis are the most common forms 
of cell death induced by IR, however, the relationship 
between the dose and a specific type of cell death is still 
under active investigation [62, 63]. In our model, low 
doses of 0.6 Gy induced an apoptotic cell death with 
caspase 3/7 activation. However, although high doses of 
Figure 5: IR-induced miRNA expression profile in colorectal cancer cells. Volcanoplot of miRNA expression profile obtained 
from a PCR array of DLD-1 cells, 48 h after exposure to (A) 0.6 Gy and (B) 12 Gy compared to non-irradiated cells (control). Overexpressed 
miRNAs (Fold Change ≥2×, red spot) and underexpressed (Fold change ≤2, green spot) with adjusted P < 0.05 are labeled. (C) Venn 
diagram comparing differentially expressed miRNAs in DLD-1 cells irradiated with 0.6 and 12 Gy.
Oncotarget26394www.oncotarget.com
12 Gy also induced an activation of these caspases, an 
important necrotic death component was evidenced 48 h 
after irradiation. Given that necrotic cell death involves an 
inflammatory response, frequently reported as an adverse 
effect of RT [5, 6, 64], the use of radiation protocols that 
trigger apoptotic cell death (without inflammation) are 
essential to improve the tumor’s regression.
It has been suggested that one possible mechanism 
underlying the LDHRS phenomenon is related to the 
presence of DNA damage [26, 65], specifically double 
strand breaks (DSB), as described for high doses of 
ionizing radiation [66, 67]. In our hands, DLD-1 cells 
exposed to 0.6 Gy showed a significant increase in 
γ-H2AX foci from 30 min up to 3 h, which also correlated 
with an increase in some DNA damage response proteins, 
including pP53, pCHK1 and pCHK2. However, γ-H2AX 
levels decreased and become similar to control groups 
6 h after irradiation (Figure 3A and 3B). On the contrary, 
γ-H2AX levels were higher and sustained in cells exposed 
to 12 Gy (Figure 3A and 3B). These results suggest that 
either DNA damage induced by 0.6 Gy is early repaired or 
that those cells containing DNA damaged were eliminated. 
Other studies have shown that both human fibroblast [35] 
and fibrosarcoma cells [34] display a lineal increase in 
γ-H2AX foci formation after 0.002 Gy IR. Nevertheless, 
foci disappear after 8 h in both cell lines. Even in DLD-
1 cells exposed to low doses of pulsed X-rays, an early 
increase in DSB had been reported (30 min), however after 
2 h, levels of γ-H2AX foci become similar to unirradiated 
control [68]. Our findings, according to these reports, 
support the idea that nuclear DNA damage induced by 
low IR doses is indeed repaired. A plausible explication 
for cell death observed even when DNA damage has 
been repaired; rely on the indirect effect of ionizing 
radiation on free radical formation and mitochondrial 
damage. As mitochondrial DNA lacks histones, it is more 
susceptible to oxidative and radiation-induced damage, 
that culminate in impaired membrane potential [69, 70]. 
Indeed, in hippocampal neurons and fibroblast-like cells, 
low-doses of radiation altered mitochondrial dynamics 
through upregulation of fission protein dynamin-related 
protein 1 (Drp1) [71, 72], a protein related with increase 
of apoptosis [73]. 
On the other hand, in cells exposed to 12 Gy, 
γ-H2AX levels and foci were still increased at 48 h after 
IR, suggesting a distinct IR-induced cell death mechanism 
for low-dose ranges. 
Several studies have evaluated the change in 
expression of miRNAs at high doses of radiation in 
colon-derived [39] and other cell lines [48, 74–76], but 
little information is available about changes in miRNA 
expression in response to low-dose IR. The evaluation 
of miRNA expression requires the use of an adequate 
housekeeping control gene. This implies a reproducible, 
reliable and stable endogenous control for a correct 
comparison with the expression of other miRNAs. Most 
published works evaluating miRNA expression have used 
small nuclear RNA (i.e. RNU6B, RNU48), however their 
properties, stability and size are different from miRNAs 
[77]. Other housekeeping genes frequently used are the 
miRNAs: let-7, miR-16, miR-423 and miR-374, among 
others, but the use of a single miRNA to normalize data 
Table 1: Fold change and adjusted p value of microRNAs differentially expressed at 0.6 Gy
miRNAs Over-expressed





miRNA Fold Change Adj P-value
miR-134-5p –6.3203 0.034752
miR-122-5p –34.0598 0.000107
Table 2: Fold change and adjusted p value of microRNAs differentially expressed at 12 Gy
miRNAs Over-expressed






may induce a systematic error [78]. To minimize data 
variation, the use of multiple miRNAs has been suggested 
together with a geometric mean to normalize them [79]. 
For this reason, our data were normalized by the geometric 
mean of 6 miRNAs (RNU6B, RNU5G, miR-423-5p, 
miR191-5p, miR-16-5p and let-7a). These miRNAs were 
analyzed using NormFinder [80] and they showed the 
lowest variation between samples (data not shown). 
In order to validate PCR-array results, we evaluated 
the expression of some target genes belonging to the most 
differentially expressed miRNAs (VEGF-A, PKCε, MMP9 
and NOD2 as targets of miR-205-3p, miR-1, miR-133b 
and miR-122-5p, respectively). These targeted mRNAs 
were chosen for their role in oncogenesis and because 
they have been previously validated in the literature, with 
the exception of VEGF-A (a miR-205-3p target). As we 
expected, targets of the overexpressed miRNAs displayed 
a significant down-regulation (Figure 6A and 6C). 
Although levels of expression of PKCε did not reach a 
significant difference, a slight decrease was evident when 
compared to the control and 12 Gy. Nevertheless, PKCε 
was validated as a target of miR-1 in cardiac ischemia (in 
mouse model) [55], therefore, it is plausible that miR-1 
could be targeting different mRNAs in colorectal cancer.
The most increased miRNA at low doses, miR-
205-3p, is expressed together with miR-205-5p mostly in 
breast, prostate and thymus cancers [81] as well as both 
miRNAs are significantly increased in non-small cell 
lung carcinoma and squamous cell carcinoma [82]. Most 
publications have focused on miR-205-5p and its dual role 
in cancer. MiR-205-5p has been reported as oncomiR in 
lung [83] and nasopharyngeal cancers [84] by targeting 
PTEN [85]. Also a role as a tumor suppressor has been 
described for miR-205-5p in prostate [86, 87], breast [88], 
melanoma [89], glioblastoma [90] and colon cancers [91] 
by targeting cMYC [92], PKCε [86], and VEGF-A [90]. 
Interestingly, in DLD-1 cells exposed to low doses of 
radiation (<1 Gy) miR-205-3p reduced proliferation and 
Figure 6: Expression levels of target mRNA in cells exposed to low and high-dose IR. mRNAs targeted by: (A) MiR-205-
3p (VEGFA), (B) miR-1 (PKCε), (C) miR-133b (MMP9) and (D) miR-1225p (NOD2), were evaluated by RTqPCR in DLD-1 cells, 48 h 
after irradiation with 0 (Control), 0.6 and 12 Gy. Expression levels were normalized to HPRT housekeeping gene. Means ± S.D of at least 
3 independent experiments are shown. Results are presented relative to control. *P < 0.05, Two-way ANOVA.
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Figure 7: miR-205-3p increases radiosensitivity at low doses of radiation. (A) DLD-1 cells were mock-transfected or transfected 
with a scrambled miR control, an anti-miR-205-3p (inhibitor) or a miR-205-3p mimic. Viability was evaluated 48 h post irradiation with 
0, 0.6 or 12 Gy, by MTS assay. Results are expressed as a percentage of mock-transfected non-irradiated cells (0 Gy). (B) Proliferation 
(mitotic index) was determined by quantifying cells with positive staining for phosphor-histone H3 in mock and mimetic transfected 
cells, 48 hours after irradiation. (C) Cell death was evaluated by trypan blue exclusion assay in mock and mimetic transfected cells, 
48 hours after irradiation. Data represent percentage of cell death in each condition. (D) Effect of miR-205-3p on apoptosis was evaluated 
by quantification of subG1 population in mock and mimetic transfected cells, 24, 48 and 72 hours after irradiation. (E) Evaluation of 
nuclear morphology of mock and mimetic transfected DLD-1 cells, 72 hours after irradiation (12 Gy). Nuclei were stained with DAPI 
(Red) and cytoplasm with α-tubulin (white). Green head arrows points to fragmented nuclei, features typical of mitotic catastrophe. Scale 
bar: 50 μm. (F) Cells with mitotic catastrophe morphology were counted in 5 different fields and normalized to the number of cells. At 
least 100 cells were evaluated per sample. Data represent the means ± S.D. of at least 3 independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001 using Two way ANOVA (A and D) or T-test (B, C and F).
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induced cell death with an important apoptotic component. 
Even when little information is available for miR-205-3p 
in the literature, with no experimental validated targets, 
in silico analysis for predicting targets of miR-205-3p 
showed that 17 out of 33 validated targets for miR-205-
5p could also be targets for miR-205-3p (DDX5, ZEB1, 
BCL2, VEGF-A, ESRRG, KCNJ10, SMAD4, ERBB3, 
AR, LRRK2, YES1, SMAD1, ACSL4, PTEN, HMGB3, 
PHLPP2, YY1) suggesting a similar function for both 
miRNAs (miRbase and TargetScan 7.1). Additionally, 
DDX3X gen (DEAD-box polypeptide 3) was the target 
with higher probability to be regulated by miR-205-3p. In 
breast cancer, DDX3X had been associated with ephitelial-
mesenchymal transition [93], while in gallbladder cancer 
promote metastasis to lymphatics nodes [94]. In HCT116 
and HT-29 colon cancer cells, inhibition of DDX3X 
reduces proliferation, presumably by involving the Wnt 
pathway [95–97].
MiR-122-5p was the most decreased miRNA in 
response to 0.6 Gy. In healthy livers, miR-122 is elevated 
and represents 70% of the total miRNA pool while it is 
diminished in liver tumors [98]. Over-expression of miR-122 
in liver cells suppresses proliferation and induces apoptosis 
[99–101]. The functions of miR-122 in colon cancer cells 
or its role in radiosensitivity have not been documented. 
However, an increase in miR-122 expression was reported 
in liver metastasis from colorectal cancer although was 
undetectable in primary tumors or in normal mucosa from 
patients [102]. This result suggests that miR-122 may act 
as an oncomiR in colorectal cancer and, therefore, may be 
down-regulated at low doses of radiation in DLD-1 cells. 
MiR-134-5p was another miRNA whose levels 
displayed a major decrease in response to 0.6 Gy. MiR-
134-5p is a brain-enriched miRNA, with an important role 
in the development and differentiation of the vertebrate 
central nervous system [103]. Overexpression of miR-
134 promotes proliferation and inhibition of apoptosis 
in lung cancer [104] as well as head and neck squamous 
cell carcinoma cells [105], while in glioblastoma [106] 
and colorectal cancer cells [107] has the opposite effect, 
promoting apoptosis and reducing proliferation. In 
addition, differential miRNA expression has also been 
reported in human B lymphoblastic [108] and peripheral 
blood mononuclear cells [47] exposed to different IR 
doses. This suggests that levels of miRNAs are IR dose-
dependent since they are a reflection of differential gene 
Figure 8: miR-205-3p overexpression increases LDHRS in DLD-1 cells. DLD-1 cells were mock-transfected or transfected 
with a mimetic miR-205-3p 24 hours before irradiation with different doses and clonogenic assay was performed. In (A) representative 
pictures of crystal violet stained colonies obtained under each condition are shown. In (B) colonies with diameters ≥200 μm (≈50 cells) 
were counted using Gen5 Software and survival fraction was calculated as in Figure 1. Results are expressed relative to the mock-
transfected group under non-irradiation conditions (0 Gy). Means ± S.D. of at least 3 independent experiments are shown. **P < 0.01; 
***P < 0.001, using two-way ANOVA.
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expression and pathway activation. The exact function of 
miR-134 in response to IR is unknown and further studies 
are necessary to determine its role as an oncomiR or tumor 
suppressor.
MiR-218-5p, a tumor suppressor miRNA, was the 
most over-expressed miRNA in response to 12 Gy. This 
miRNA is down-regulated in different cancers [109] and 
transfection with a miR-218-5p mimic inhibits migration 
and proliferation in non-small-cell lung cancer cells by 
targeting the epidermal growth factor receptor (EGFR) 
[110]. In colorectal cancer cells, miR-218-5p reduced 
migration, invasion and colony formation by targeting 
the Metastasis Associated with Colon Cancer 1 protein 
(MACC1) [111].
Interestingly, miR-1 was the only miRNA that 
significantly increased at both 0.6 and 12 Gy IR doses. 
MiR-1 is abundantly expressed in cardiac and skeletal 
muscle tissue [112] and its expression is down-regulated in 
several solid cancers: testes, colon, lung, ovary, lymphoma 
and prostate [113].
In HT-29 and HTC-116 colorectal cancer cells, 
miR-1 acts as a tumor suppressor, reducing proliferation 
and migration by targeting the c-MET oncogene 
(Hepatocyte growth factor receptor) [114], a member of 
the MAPK pathway [115]. Similarly, Xu et al. showed 
that overexpression of miR-1 in HT-29 and Caco2 cells 
suppressed aerobic glycolysis by targeting Smad3, a 
critical protein for HIF-1α signaling, causing a reduction 
in proliferation [116]. Furthermore, transfection with miR-
1 in cardiomyocytes induces apoptosis by targeting the 
anti-apoptotic protein Bcl-2 [117]. All this data suggests 
that, in DLD-1 cells, miR-1 may be inducing apoptosis in 
response to low and high-dose radiation.
Interestingly, in cells exposed to 12 Gy, miR-
205-3p displayed an augmented number of multi- and 
micronuclei, a morphological feature associated with 
mitotic catastrophe [118, 119]. This observation suggests 
that at low doses miR-205-3p induce cell death by 
apoptosis, but at high doses could augment mitotic 
catastrophe. Here, the effect of miR-205-3p was also 
evaluated in different cell lines (Supplementary Figure 
2), finding distinct effects, at different doses, in each cell 
line analyzed. Although confusing, this data reinforce the 
concept that radiation sensitivity is not driven solely by 
gene expression, but rather by a combination of distinct 
parameters, including cell type and radiation dose [120].
To date, most studies have evaluated the effect of 
different miRNAs on radiosensitivity using high doses 
of radiation (> 1 Gy), however this strategy does not 
consider the adverse effect observed in clinical protocols. 
Neglia et al. reported an increased relative risk of 0.69 
per Gy for all central nervous system tumors when a 
cohort of 5-year survivors of childhood cancer were 
exposed at doses >1 Gy/daily [121]. In vitro experiments 
showed a lineal relationship between transformation and 
radiation doses ranging from ~1 to ~4–5 Gy, while no 
transformation effect was detected below 0.1 Gy [122]. In 
this context, LDHRS appears as an opportunity to improve 
the therapeutic effect of RT while reducing the adverse 
effects. We found that miR-205-3p, the most augmented 
miRNA in response to 0.6 Gy, could significantly increase 
the radiosensitivity of DLD-1 cells, maximizing the 
LDHRS phenomenon. 
The precise mechanism that miR-205-3p uses to 
trigger apoptosis is unknown, nor are its targets in colon 
cancer cell lines. Further functional analysis will be 
necessary to elucidate the role of differentially expressed 
miRNAs in LDHRS, as well as the molecular mechanism 
involved in its expression under these ionizing radiation 
conditions. Meanwhile, the data presented here might 
contribute to strengthen efforts on building algorithms 
based on the integration of gene expression data and 
other biological and clinical parameters, aimed to predict 
the radiosensitivity and enhancing the outcome for each 
particular patient [36, 120, 123–127].
MATERIALS AND METHODS
Cell culture and viability assays 
DLD-1 human colorectal cancer cells were 
cultured in RPMI1640 (Mediatech, Herndon, VA, 
USA) supplemented with 10% heat-inactivated fetal 
bovine serum (Mediatech), penicillin G (100 U/ml), and 
streptomycin (100 µg/ml) and incubated in a 5% CO2 
humidified atmosphere at 37° C. Media was changed 
every 3 days and cells were trypsinized when they 
reached 80%–90% confluence. Cells were seeded in 96-
well plates at a density of 2 × 103 cells/well. After ionizing 
radiation, 20 µL of MTS plus 1 µL PMS (Cell Titer 96 
Aqueous, Promega, Madison, Wl, USA) were added to 
each well, followed by incubation for 3 hours at 37° C. 
The plates were mixed for 30 seconds and absorbance was 
measured at 490 nm (Cytation 3™, BioTek instruments, 
Winooski, VT, USA). Viability was also evaluated by 
mixing cells with an equal volume of 0.4% trypan blue 
solution (Logos Biosystems, Gyunggi-Do, Korea). Cells 
were counted using a LUNA™ Automated Cell Counter 
(Logos Biosystem). All assays were performed at least 
three times.
Cell irradiation
Cells were irradiated with 60Co sources at the 
Comisión Chilena de Energía Nuclear (CCHEN). For 
doses lower than 1 Gy, a Noratom 3500 at 0.15 Gy/min 
was used. For high doses, a Gammacell 220R (Nordion) 
at 20 Gy/min was used. After irradiation, cells were split 
for the following assays. 
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Caspase 3/7 and citotoxicity assay
Citotoxicity and caspase activity was measured 
using the ApoTox-Glo Triplex assay kit (Promega, 
Madison, WI, USA). Briefly, 100 µL of viability/
citotoxicity buffer was added to 2 × 103 cells on 96-well 
plates. The mixture was incubated for 30 minutes at room 
temperature, and fluorescence was determined using a 
microplate reader (Ex 485 nm/Em 520 nm) (Cytation 3™, 
BioTek instruments). After reading, 100 µL of caspase 
3/7 substrate (Z-DEVD) was added and the mixture 
was incubated for 30 minutes at room temperature, and 
luminescence was evaluated.
Indirect immunofluorescence
Two-days after irradiation, cells grown on glass 
coverslips were fixed using 4% p-formaldehyde for 10 
minutes, permeabilized with 0.25% Triton X-100 at 
room temperature and blocked with 3% BSA/PBS for 45 
minutes. Cells were incubated overnight with an anti-γ-
H2AX antibody (1:1000, Millipore, Temecula, CA, 05-
636), anti-phospho Histone H3 (Ser10, 1:1000, Millipore, 
Temecula, CA, 06-570) or anti-α-tubulin (1:5000, 
ThermoFisher Scientific, Illinois, USA, PA5-22060) 
prepared in 0.05% Triton X-100 and 1% BSA/PBS. After 
washing, cells were incubated with an anti-mouse Alexa 
Fluor-488 secondary antibody (1:500, Molecular Probes, 
A-21042) or anti-rabbit Alexa Fluor-488 secondary 
antibody (1:500, Invitrogen A-11034). Slides were 
mounted with ProLong Gold Antifade Reagent with DAPI 
(Life Technologies, NY). Cells were photographed under 
a fluorescence microscope (BX53; Olympus, Japan). For 
γ-H2AX quantification, foci were counted using a Find 
Maxima plugin and normalized by nuclei numbers using 
ImageJ software (Rasband, National Institutes of Health, 
USA). Every focus bigger than 0.1 μm (13 pixels) was 
considered as positive.
Cell cycle analysis
A day before irradiation, 2.4 × 104 cells/well on 
6-well plates were seeded. After irradiation, cells were 
collected by trypzinization at 24, 48 and 72 h, and then 
fixed with 70% ethanol at 4° C for 24 h. Cells were stained 
with a DNA staining solution (50 µg/mL of Propidium 
Iodide, Sodium citrate 1% (w/v), 1% NP-40, 10 µg/mL 
of Rnase A and PBS 1X). Cell cycle distribution was 
evaluated by fluorescence-activated cell sorter FACSCanto 
(BD) and data was analyzed using FlowJo software 
(Treestar, Inc., San Carlos, CA).
Real-time quantitative PCR
Total RNA was extracted using Trizol reagent 
(Ambion, Austin, TX). MicroRNA cDNAs were prepared 
using mIRCURY LNA Universal RT microRNA (Exiqon, 
Denmark). Expression of a subset of 86 miRNAs was 
evaluated in an array platform (Supplementary Table 1) 
using ExiLENT SYBR Green master mix (Exiqon). Data 
were normalized by the geometric mean of: RNU6B, 
RNU5G, miR-423-5p, miR191-5p, miR-16-5p and let-7a. 
For miRNA profiling, a 2-fold increase or decrease with 
adjusted P < 0.05 was considered significant. 
For validation studies, cDNAs were prepared using 
Affinity Script qPCR (Agilent Technologies, Santa Clara, 
CA, USA) and quantified using Brillant II Sybr (Agilent) 
in an Eco™ Real-time PCR System (Illumina Inc., 
San Diego, CA, USA). The target’s mRNA levels were 
normalized to HPRT levels and expressed as 2–ΔΔCt. Data 
represent at least three independent experiments and each 
sample was measured in duplicate. The specific primers 
used for qPCR are show in Supplementary Table 2. 
Western blotting
Cells were lysed in a RIPA buffer and 30 g proteins 
were loaded and separated in sodium dodecyl sulfate–
polyacrylamide electrophoresis (SDS–PAGE) gels and 
transferred onto nitrocellulose membranes (Thermo 
Scientific, Rockford, IL, USA). After blocking with 
TBS-T containing 5% BSA, membranes were incubated 
overnight at 4° C with the following antibodies: Anti 
γ-H2AX (1:1000, Millipore, Temecula, CA), phospho-P53 
(1:2000), P53 (1:2000), phospho-Chk1 (1:2000), phospho-
Chk2 (1:2000), Chk1 (1:2000) and Chk2 (1:2000) from 
Cell Signaling (Danvers, MA). Anti-β-actin (1:10.000, 
Sigma, St Louis, MO) was used as a loading contrtol. 
Transient transfection of cells with miR-205-3p 
mimic 
Cells were seeded in 6-well plates (6 × 104 cells 
per well) in 500 µL of RPMI-1640 plus supplements and 
transfected with 5 nM of a miR-205-3p mimic (purchased 
from Qiagen, Crawley, UK) using HiPerFect Transfection 
Reagent (Qiagen) according to the manufacturer’s 
protocol. miR-205-3p transfection efficiency was assessed 
by qPCR from 24 h to 72 h post-transfection and by 
transfecting a EGFP-tagged small RNA.
Prediction of mRNAs targeted by miR-205-3p
In order to predict the potential miR-205-3p´s 
targets, algorithms from miRbase (http://www.mirbase.
org) and TargetScan 7.1 (http://www.targetscan.org/
vert_71) were used. 
Clonogenic survival assay
DLD-1, HT29, MCF7 and MCF10a cells transfected 
with the mimetic miR-205-3p were seeded at a density 
of 500-1000 cells per 6-wells plate and 3 hours later, 
exposed to 0, 0.3, 0.6, 1, 6 and 12 Gy. Irradiated cells 
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were incubated for 10–14 days and then fixed with 
10% of p-formaldehyde for 10 minutes and stained with 
0.5% crystal violet for 30 minutes. Excess of dye was 
raised with PBS and the number of colonies, greater 
than 50 cells, was counted as surviving colonies, using 
the Gen5 software (supplied with the Biotek Cytation3). 
The survival fraction at each doses were calculated as 
previously described [10, 128].
Data analysis for survival assays
The surviving fraction (S) data at all doses tested, 
were fitted to linear-quadratic (LQ) and induced-repair 
(IR) model (Equation 1), using nonlinear least squares 
regression through the iterative method of Gauss-Newton 
with step halving (Python Software).
Equation 1: S D exp D D( ) { }= − −α β 2 [61, 129]






























exp 1 1 2β  [11, 21–23];
where d is the dose of radiation used, ar, is the slope 
extrapolated from high dose response, aS is the survival 
curve slope measured at low doses, Dc is the transition 
from LDHRS to IRR response and β is a constant, as in 
the linear-quadratic equation 
Statistical analysis
Data are represented as the means ± S.D. of at least 
three independent experiments. The statistical significance 
between experimental and control groups was calculated 
using two-way ANOVA followed by Dunnet’s multiple 
comparision test. For miRNA profiling, the statistical 
significance between irradiated and control groups was 
analyzed using Student’s t test and Adjusted P-value was 
calculated using Sidak-Bonferroni post-test. Graphpad 
Prism V6.0 (GraphPad Software, San Diego, CA) was 
used to perform all analyses and graph data. A P < 0.05 
was considered significant. 
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